Stock Report: Luminex Corp. (LMNX) Report Updated: May 20, 2013 | Print This Page

Luminex Corporation engages in the development, manufacture, and sale of proprietary biological testing technologies and products for the life sciences and diagnostic industries. It offers xMAP technology, an open architecture and multiplexing technology that allows simultaneous analysis of approximately 500 bioassays from a drop of fluid by reading biological tests on the surface of microscopic polystyrene beads called microspheres. The company’s xMAP technology is used in various segments of the life sciences industry, such as the fields of drug discovery and development, clinical diagnostics, genetic analysis, bio-defense, food safety, and biomedical research. It operates in two segments, Technology and Strategic Partnerships; and Assays and Related Products. The Technology and Strategic Partnerships segment provides Luminex LX 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; and MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids. This segment also offers consumables comprising dyed polystyrene microspheres and sheath fluids. The Assays and Related Products segment develops and sells assays on xMAP technology for use on its installed base of systems. This segment’s products are focused on the human genetics, personalized medicine, and infectious disease segments of the genetic testing market. This segment provides various assay products, which consist of a combination of chemical and biological reagents, and company’s proprietary bead technology used to perform diagnostic and research assays on samples. It serves pharmaceutical companies, clinical laboratories, research institutions, and medical institutions in the United States, Europe, Asia, Canada, and Australia. The company was founded in 1995 and is headquartered in Austin, Texas.